Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/scd.2020.0114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.
Nat Cancer
January 2025
Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Cancer Cluster Salzburg, Salzburg, Austria.
The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination partners with immunotherapies. In the randomized phase 2 trial ABCSG-52 (EudraCT no.
View Article and Find Full Text PDFPorous Silicon on Paper: A Platform for Quantitative Rapid Diagnostic Tests.
ACS Appl Mater Interfaces
January 2025
Interdisciplinary Material Science Program, Vanderbilt University, Nashville, Tennessee 37235, United States.
Porous silicon (PSi) thin films on silicon substrates have been extensively investigated in the context of biosensing applications, particularly for achieving label-free optical detection of a wide range of analytes. However, mass transport challenges have made it difficult for these biosensors to achieve rapid response times and low detection limits. In this work, we introduce an approach for improving the efficiency of molecule transport in PSi by using open-ended PSi membranes atop paper substrates in a flow-through sensor scheme.
View Article and Find Full Text PDFFlow Cytometry Analysis of Perturbations in the Bacterial Cell Envelope Enabled by Monitoring Generalized Polarization of the Solvatochromic Peptide UNR-1.
Anal Chem
January 2025
Laboratoire d'Innovation Thérapeutique, UMR7200 CNRS, Université de Strasbourg, Institut du Médicament de Strasbourg, 74 route du Rhin, Strasbourg F-67000, France.
The worldwide spread of antibiotic resistance is considered to be one of the major health threats to society. While developing new antibiotics is crucial, there is also a strong need for next-generation analytical methods for studying the physiological state of live bacteria in heterogeneous populations and their response to environmental stress. Here we report a single-cell high-throughput method to monitor changes in the bacterial cell envelope in response to stress based on ratiometric flow cytometry.
View Article and Find Full Text PDFComparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France.
J Antimicrob Chemother
January 2025
Service de santé publique, Inserm CESP U1018, Université Paris-Saclay, APHP. Université Paris-Saclay, le Kremlin-Bicêtre, France.
Background: Therapeutic outcomes for patients infected by genetically divergent HIV-1/O are not well-known due to scarce data and the lack of an appropriate comparison with patients infected by pandemic HIV-1/M. We aimed to compare the immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed in France.
Methods: All naïve HIV-1/O subjects initiating cART in France in ANRS-ORIVAO study were compared to naïve HIV-1/M subjects initiating cART in ANRS-COPANA cohort.
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.
Vaccine
January 2025
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Introduction: While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.
Methods: A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!